Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N6C: Neoadjuvant Albumin-Bound Paclitaxel and Carboplatin in Cervical Cancer
NCT05367206Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in Cervical Cancer (CC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: 3-year progression-free survival ratio. Started Mar 2022; status: recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05367206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367206.